Table 4.

Correlation of baseline pSTAT levels and total STAT1 and STAT3 expression levels with improvement in DAS28 during 3-month treatment with tofacitinib and csDMARDs.

Molecule	Stim.	Cell type
		Monocytes		CD4+ T cells		CD4- T cells		B cells
		r	p	r	p	r	p	r	p
pSTAT1	None	0.591	0.016	0.603	0.013	0.391	0.134	0.280	0.294
pSTAT1	IFN-γ	0.379	0.147	0.532	0.034			0.062	0.820
pSTAT1	IFN-α	-0.079	0.770	-0.150	0.579	-0.088	0.745	0.038	0.888
pSTAT1	IL-6	0.556	0.025	0.282	0.289
pSTAT3	None	0.635	0.008	0.732	0.001	0.424	0.102	0.426	0.099
pSTAT3	IL-6	0.385	0.141	0.621	0.010	0.126	0.641
pSTAT3	IL-10	0.253	0.345	0.224	0.405	0.185	0.492	0.224	0.405
pSTAT3	IL-21			0.115	0.672	-0.009	0.974	0.085	0.753
pSTAT4	None	-0.506	0.046	-0.491	0.053	-0.518	0.040	-0.344	0.192
pSTAT4	IFN-α			-0.568	0.022	-0.638	0.008
pSTAT5	None	0.350	0.184	0.568	0.022	0.271	0.311	0.276	0.300
pSTAT5	IL-2			0.147	0.587	0.159	0.557
pSTAT5	IL-7			0.026	0.922	-0.147	0.587
pSTAT5	IL-15			0.162	0.549	0.147	0.587
pSTAT6	None	-0.175	0.517	-0.130	0.633	-0.219	0.414	0.218	0.418
pSTAT6	IL-4	-0.082	0.762	-0.300	0.259	-0.412	0.113	-0.279	0.295
STAT1	None	-0.291	0.274	-0.356	0.176	-0.488	0.055	-0.212	0.431
STAT3	None	-0.307	0.265	-0.354	0.196	-0.479	0.071	-0.432	0.108

Spearman correlation coefficients (r) are used. Results with p-values ≤0.05 are shown in bold. Spaces left empty denote the cases in which the stimulated phosphorylation level does not differ from the constitutive level.

DAS28, composite Disease Activity Score for 28 joints based on the C-reactive protein level (DAS28-4[CRP]); csDMARD, conventional systemic disease-modifying antirheumatic drug; IFN, interferon; IL, interleukin; (p)STAT, (phosphorylated) signal transducer and activator of transcription; stim., stimulation.